M. Holzer , N. Ruffer , I. Pinal-Fernandez , F. Kleefeld , H. Goebel , A. Schänzer , M. Casal-Dominguez , I. Kötter , N. Görl , R. Alten , E. Braasch , T. Lempert , A. Krause , T. Huber , T. Liewluck , A. Mammen , W. Stenzel , C. Preuße , U. Schneider , M. Krusche
{"title":"23PMyopathology and immune profile of granulomatous myositis in sarcoid myopathy","authors":"M. Holzer , N. Ruffer , I. Pinal-Fernandez , F. Kleefeld , H. Goebel , A. Schänzer , M. Casal-Dominguez , I. Kötter , N. Görl , R. Alten , E. Braasch , T. Lempert , A. Krause , T. Huber , T. Liewluck , A. Mammen , W. Stenzel , C. Preuße , U. Schneider , M. Krusche","doi":"10.1016/j.nmd.2025.105486","DOIUrl":null,"url":null,"abstract":"<div><div>Sarcoid myopathy (SaM) is characterized by granulomatous myositis and can overlap with inclusion body myositis (IBM), a late-onset chronic idiopathic inflammatory myopathy with a still enigmatic pathogenesis. Systematic studies assessing the myopathologic features of SaM are scarce and the immunopathogenesis of muscle inflammation in SaM is poorly understood. In this context, we performed a multidimensional characterization of muscle biopsy specimens from patients with ‘pure SaM’, SaM with concomitant IBM (SaM-IBM) and ‘pure IBM’ including histopathologic and ultrastructural analysis in addition to molecular profiling. Myopathologic analysis revealed a prototypical appearance of SaM that is characterized by endomysial and perimysial granulomatous inflammation frequently extending to the fascia, endomysial fibrosis, muscle fibre atrophy, variations of muscle fibre size and capillary thickening. Findings from immunohistochemical studies established Chitinase 1 as a pure giant cell marker in SaM. In addition, SaM is characterized by disease-specific immune dysregulation that involves macrophage function and maturation. Finally, SaM-IBM represents a noteworthy overlap syndrome that shares multiple dysregulated immune pathways with ‘pure SaM’.</div></div>","PeriodicalId":19135,"journal":{"name":"Neuromuscular Disorders","volume":"53 ","pages":"Article 105486"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromuscular Disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960896625002135","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sarcoid myopathy (SaM) is characterized by granulomatous myositis and can overlap with inclusion body myositis (IBM), a late-onset chronic idiopathic inflammatory myopathy with a still enigmatic pathogenesis. Systematic studies assessing the myopathologic features of SaM are scarce and the immunopathogenesis of muscle inflammation in SaM is poorly understood. In this context, we performed a multidimensional characterization of muscle biopsy specimens from patients with ‘pure SaM’, SaM with concomitant IBM (SaM-IBM) and ‘pure IBM’ including histopathologic and ultrastructural analysis in addition to molecular profiling. Myopathologic analysis revealed a prototypical appearance of SaM that is characterized by endomysial and perimysial granulomatous inflammation frequently extending to the fascia, endomysial fibrosis, muscle fibre atrophy, variations of muscle fibre size and capillary thickening. Findings from immunohistochemical studies established Chitinase 1 as a pure giant cell marker in SaM. In addition, SaM is characterized by disease-specific immune dysregulation that involves macrophage function and maturation. Finally, SaM-IBM represents a noteworthy overlap syndrome that shares multiple dysregulated immune pathways with ‘pure SaM’.
期刊介绍:
This international, multidisciplinary journal covers all aspects of neuromuscular disorders in childhood and adult life (including the muscular dystrophies, spinal muscular atrophies, hereditary neuropathies, congenital myopathies, myasthenias, myotonic syndromes, metabolic myopathies and inflammatory myopathies).
The Editors welcome original articles from all areas of the field:
• Clinical aspects, such as new clinical entities, case studies of interest, treatment, management and rehabilitation (including biomechanics, orthotic design and surgery).
• Basic scientific studies of relevance to the clinical syndromes, including advances in the fields of molecular biology and genetics.
• Studies of animal models relevant to the human diseases.
The journal is aimed at a wide range of clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.